Australian biotech market watch 12/06/09
Friday, 12 June, 2009
The All Ordinaries has continued its rally, gaining half a percent in trading up to 3pm this afternoon, although most of the gains were in property and finance, with the health indicies not faring as well.
Cochlear (ASX:COH) dropped fractionally, although several analysts have recently been offering a positive outlook on the stock. A heavier fall was experienced by Halcygen Pharmaceuticals (ASX:HGN), which dropped 19.4% to 25c, and SciGen, which shed 15% to 32c. Pharmaxis (ASX:PXS) also dropped 14c to $2.55 after a big day Thursday, which saw its price jump from $2.50 to $2.70.
It wasn't all bad news though, particularly for ChemGenex (ASX:CXS), which jumped 10% in response to its announcement yesterday of positive results from its clinical trials of anti-chronic myeloid leukemia drug, Omacetaxine.
CathRX (ASX:CXD) also jumped 7.1% to 60c, continuing its week-long rise following its capital raising announcement of last week. Ramsay Health Care is still meandering its way up, this time by 29c to $11.65.
Biota Holdings (ASX:BTA) is up 6.3% to $1.35 following its announcement that its phase IIa challenge study of BTA798, an orally active inhibitor of human rhinovirus (HRV), was successful in demonstrating proof-of-concept in humans.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
